Diabetes Clinical Trials in San Antonio

Showing 221-240 of 283 trials

Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes

NCT00071422

Insulin is a chemical that the body needs in order to use or store sugar. It is made by a type of cell called a beta cell which resides in an organ known as the pancreas. Type 2 diabetes is a disease where the beta cells are unable to meet a person's insulin needs. Sugar levels rise in the blood as a result. INGAP-Peptide is being tested to attempt to create new beta cells in the pancreas, and to improve the ability to produce insulin in type 2 diabetic patients.

Diabetes Mellitus, Non-Insulin-Dependent

Exsulin Corporation126 participantsStarted Oct 2003

La Jolla, California, United States • San Diego, California, United States • Walnut Creek, California, United States +14 more locations

COMPLETEDPHASE3< 1 mile

Dapagliflozin DPPIV Inhibitor add-on Study

NCT00984867

This study aims to investigate how dapagliflozin can control blood sugar in patients with type 2 diabetes when added to existing treatments (sitagliptin alone or in combination with metformin). The effect of dapagliflozin on weight and blood pressure will also be studied.

Type 2 Diabetes

AstraZeneca833 participantsStarted Oct 2009

Huntsville, Alabama, United States • Ozark, Alabama, United States • Anaheim, California, United States +85 more locations

Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes

Dapagliflozin DPPIV Inhibitor add-on Study

Diabetes Trials in Other Cities

Markers and Mechanisms of Vascular Disease in Type II Diabetes

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (Explores What the Body Does to the Drug), and Pharmacodynamics (Explores What a Drug Does to the Body) of JNJ-38431055 in Volunteers With Type 2 Diabetes Mellitus

Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes

A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients

Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone

Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes

Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis

Diabetes and Periodontal Therapy Trial

A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus

Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic Therapy

A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes

Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Type 2 Diabetes Mellitus

Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus

A Trial of TT223 in Patients With Type 2 Diabetes Who Are Taking Metformin and/or Thiazolidinedione

Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 Diabetes

Safety and Pharmacokinetics of CBX129801 in Patients With Type 1 Diabetes

Impact of a Diabetes Risk Score on Lifestyle Education and Patient Adherence

Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension

Other Conditions in San Antonio